News
Australian diagnostics company to launch “world’s first” risk test for breast and ovarian cancer
The test is performed from a single saliva sample and aims to inform women of their risk profile
The Australian diagnostics company Genetic Technologies Limited is preparing to launch “world’s first” risk assessment test for breast and ovarian cancer.
The test evaluates women’s risk of developing breast and ovarian cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.
The company says this approach “appends” the detection of the 13 major actionable breast and ovarian cancer susceptibility genes to its cancer test platform, advancing the goal of providing population-based genetic screening.
Globally, there are more than 2.26 million cases of breast cancer and 313,000 cases of ovarian cancer diagnosed annually.
In the US there are 297,790 new cases of invasive breast cancer that are diagnosed annually and 19,880 women diagnosed with ovarian cancer.
Currently women are under-screened and underdiagnosed for risk of hereditary breast and ovarian cancer syndrome (HBOC) based on their clinical criteria.
There is considerable evidence that these criteria do not capture all women who are HBOC carriers.
One recent general population screen among more than 6,000 women found that of 38 HBOC carriers identified nearly half would not have qualified for HBOC testing based on clinical criteria and their elevated risk of cancer would not have been identified.
The risk assessment, developed by Genetic Technologies (GTG), is performed from a single saliva sample and aims to inform women of their risk profile and give them the opportunity to take proactive actions to increase screening and lessen their risk of developing the two types of cancer.
“GTG believes this comprehensive risk test for breast and ovarian cancer is one of our most important and significant contributions to the advancement of population-based genetic testing,” said CEO, Simon Morriss.
“We are moving beyond rare cancer-susceptibility genetics. We can look for the needle in the haystack, but we are also able to look at the haystack itself.
“Our non-invasive risk assessment test will address cancer risk at a population health level.”
The company says the test will be clinically validated and have appropriate regulatory approval and will be showcased at the BRCA 2023 Symposium in Montreal in May.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







7 Comments